Comparative Pharmacology
Head-to-head clinical analysis: DRONEDARONE HYDROCHLORIDE versus SORINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRONEDARONE HYDROCHLORIDE versus SORINE.
DRONEDARONE HYDROCHLORIDE vs SORINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dronedarone is a benzofuran derivative with antiarrhythmic properties belonging to class III. It blocks multiple ion channels (K+, Na+, Ca2+) and exhibits antiadrenergic effects. It prolongs atrial refractory periods and reduces ventricular rate.
Selective beta-1 adrenergic receptor antagonist; decreases cardiac output, heart rate, and blood pressure.
400 mg orally twice daily with meals.
5 mg orally once daily, increased after 4 weeks to 10 mg orally once daily if tolerated and needed.
None Documented
None Documented
Terminal half-life is approximately 24 hours (range 13–31 hours) after multiple dosing. Steady state is reached within 4–8 days. The prolonged half-life supports once-daily dosing but requires caution in renal impairment due to accumulation of inactive metabolites.
4-6 hours in healthy adults; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 6% of an oral dose is excreted unchanged in urine. The majority is eliminated as metabolites via biliary excretion into feces (84% of total radioactivity recovered in feces, 6% in urine).
Renal (80% unchanged) and biliary (15% as metabolites); 5% fecal.
Category C
Category C
Antiarrhythmic
Antiarrhythmic